WIM
Woodford Investment Management Portfolio holdings
AUM
$310M
This Quarter Return
+4.69%
1 Year Return
-17.41%
3 Year Return
-27.69%
5 Year Return
+67.02%
10 Year Return
–
AUM
$2.72B
AUM Growth
+$2.72B
(+13%)
Cap. Flow
+$208M
Cap. Flow
% of AUM
7.64%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
6
Reduced
1
Closed
–
Top Buys
| 1 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
$71.4M |
| 2 |
AbbVie
ABBV
|
$68M |
| 3 |
Gilead Sciences
GILD
|
$44.7M |
| 4 |
Prothena Corp
PRTA
|
$15.9M |
| 5 |
Alkermes
ALKS
|
$10.3M |
Top Sells
| 1 |
Biogen
BIIB
|
$2.21M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AbbVie
ABBV
$372B
| $860M | 31.57% | 11,854,758 +937,500 | +9% | +$68M |
|
|
2
Prothena Corp
PRTA
$441M
| $617M | 22.66% | 11,400,424 +294,213 | +3% | +$15.9M |
|
|
3
Alkermes
ALKS
$4.78B
| $443M | 16.28% | 7,647,977 +177,449 | +2% | +$10.3M |
|
4
Theravance Biopharma
TBPH
$699M
| $427M | 15.67% | 10,706,180 +1,072 | +0% | +$42.7K |
|
|
5
Gilead Sciences
GILD
$140B
| $157M | 5.77% | 2,220,100 +632,000 | +40% | +$44.7M |
|
|
BIVV
6
DELISTED
Bioverativ Inc. Common Stock
BIVV
| $119M | 4.37% | 1,977,764 +1,186,500 | +150% | +$71.4M |
|
|
7
Biogen
BIIB
$19.4B
| $100M | 3.67% | 368,645 -8,143 | -2% | -$2.21M |
|